OWC Pharmaceutical Research Corp (OWCP)

[makingbank]

MUST READ

OTC DISCLOSURE & NEWS SERVICE
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to ShareholdersPress Release | 03/08/2018
OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
PR Newswire

PETACH TIKVA, Israel, March 8, 2018

PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders.

OWC Logo
In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the "Company").

The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.

We have recruited a highly skilled management team with multi-year experience in medical cannabis, pharmaceutical development, corporate management and capital markets.

As we have stated in our 8-K filing of today, we are neither a party to the pending SEC action against a former adviser to the Company, nor is the Company alleged to have been a party to nor had any knowledge of the purported scheme by the former adviser, who is the subject of the SEC action.

The Company's management is committed to and focused on our development programs which are continuing as per plan. These include inter alia, our current safety trial for our cannabis cream; the approval processes to initiate a safety trial for our oral disintegrating tablet and additional pipeline projects.

As a management team, we are committed to building value for our shareholders though professional, ethical and strategic management of a technology platform that we believe will bring improved health and quality of life to millions of patients around the world. We have recently announced the addition of our new Chief Scientific Officer and we continue to develop the resources we believe will bolster our endeavors in creating a great company.

Yours sincerely,

Dr. Stanley Hirsch
Chairman of the Board

About OWC Pharmaceutical Research Corp.
OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively 'OWC' or the 'Company') conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.

OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWCP research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

For more information visit: http://www.owcpharma.com/.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information::
Mordechai Bignitz , Chief Executive Officer – OWC Pharmaceutical Research Corp.
Email: [e-mail]
Tel: [phone]



Cision View original content:http://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-issues-chairmans-statement-to-shareholders-300610781.html

SOURCE OWC Pharmaceutical Research Corp.

[janice shell]

But,..based on what has occurred the transfer agent didn't check.

Then it's entirely possible the TA will also get into trouble. Not to mention the disbarred attorney.

If nobody's commented on it yet, the SEC finally got round to posting the Friedland suit on its website:

https://www.sec.gov/news/press-release/2018-34

Note these parts:

The investigation has been conducted by Michael T. Grimes, Keith O’Donnell, William Connolly, Shipra G. Wells, and Josh Felker, and supervised by Melissa R. Hodgman. Christian Schultz and Timothy Halloran will lead the SEC’s litigation under the supervision of Fred Block. The SEC appreciates the assistance of Financial Industry Regulatory Authority.

The SEC’s investigation is ongoing.

[I-Glow]

Why didn't Hirsch address the issue of OWCP supplying Friedland with fraudulent documents so the restrictive legend could be removed and he could deposit them in different accounts?

Why didn't Hirsch address the issue of the ongoing investigation by the SEC - doesn't seem he was being very transparent? Why did he attempt to conceal this information from investors?

Hirsch also didn't say anything about Friedland being involved with OWCP from the very beginning.

It looks very grim for OWCP and their shareholders.

IG

[MjMilo]

Um..again...no...
right from the SEC document---

"On February 23, 2017, the clearing firm for Spencer Edwards sought and
obtained an attorney opinion that relied on the information provided by Freidland, discussed
the relationship between Friedland and Global, on the one hand, and Kathy Friedland and Lane
6552, on the other, before approving the sale of the OWC stock, after which Spencer Edwards
agreed to sell the 5.1 million OWC shares. "

[Cherry]

I hope he gets locked up for the maximum time allowed and I bet someone else will be going down too and many of use longs know who it is hum !!

So glad OWC Pharmaceutical had NOTHING to do with This it should also show many investors that OWC Pharmaceutical is the Real Deal Now that the SEC has proven OWC is 100% on the up and up !!!

OWC is a GOLD MINE!

[salocpa]

If OWCP was the SEC target it would have happened already, period.

[I-Glow]

Did you read the SEC press release about the ongoing investigation - just as all those doing real DD understood.

But it was in the SEC compliant against Friedland it was apparent to all real researchers that the investigation was just getting started.

Why do you think OWCP supplied fraudulent documents to Friedland to remove the restrictive legend so he could deposit the certs in different accounts.

IG

[ChillinCharlie]

I’m transferring restricted stock as we speak. It’s a pain in the ass. Glad JF had such an easy time. Those numbers can’t be right. Investors have been selling last years PP stock like the company’s being investigated by the SEC

[I-Glow]

Please provide a link to the Sheba Dermatology department about the OWCP research on the psoriasis cream.

Odd that no one has been able to provide any information from the Sheba site about the OWCP research.

And there has never been any published research from OWCP.

Where is the big efficacy report that was supposed to be completed in March 2017 - it still hasn't been published.

IG

[John Kent]

Agreed but at the least he shoujld have disclosed he had this many shares

[John Kent]

Stay tuned for the next episode of American greed. What Jeff did was unethical pumped dumped a ton along with his pump crew and started his own company and started recruiting owcp longs over there.

[EasternTimeZone]

blah blah blah... You keep touting the 2 opinion letters provided by OWC in 2014 and then 2016 as if those were fraudulent. They weren't. The fraudulent opinion letter was provided by Jeffery Friedland in February of 2017.

I have no doubt you have also read the SEC action in it's entirety as I have. The difference is I will speak truth of facts as we know it, whereas you are purposely trying to make people think that the 2014 and 2016 opinion letters that OWC provided are the same as the 2017 fraudulent opinion letter that Jefferey Friedland provided. That's deceptive.

You keep touting this over and over as if us investors who have read the document will somehow be persuaded to believe you instead of the SEC.

I believe the SEC.

[ChillinCharlie]

That’s good news. Maybe I get some money back. Gonna call Fred Block myself

[Moonbound]

Enjoy! Good purchase

[I-Glow]

Did you get the OWCP joke - the SEC has a ongoing investigation concerning the OWCP scam.

Take a look: https://www.sec.gov/news/press-release/2018-34

Damn that is beautiful.

You have been promising to post the documents showing OWCP has been granted a patent for over a year - so far just more white noise void of facts.

As usual I posted facts about the OWCP share selling scheme - and the facts are that OWCP doesn't own any patents.

All the information will be provided to the SEC.

Looking forward to reading your DD. LMAO!

IG

[Mtmxs]

OWCP’s chairman’s statement to shareholders....

OWC Pharmaceutical Research Corp Issues Statement from
Chairman Dr. Stanley Hirschhttps://t.co/IrZvi23WhN $OWCP pic.twitter.com/Rlm25twi7Q

— OWCPharma (@OWCPharma) March 8, 2018

[I-Glow]

Don't be concerned - I have much more information to share with the SEC about the OWCP scam - they missed a few things that will help wrap up OWCP on the greys.

IG

[EasternTimeZone]

Jeffery Friedland was an Advisory Board Member. He acted fraudulently with his documentation and opinion letter which he provided to the OWC transfer agent in January 2017. He then continued to be fraudulent with a broker, and then a second broker.

[I-Glow]

So you wanted a link about the ongoing investigation - here it is:

https://www.sec.gov/news/press-release/2018-34

Hope that helps.

"The SEC’s investigation is ongoing."

IG

[KGMoney]

I always thought Jeff Friedland was a clown. He jacked up last years Wall Street Con yapping his mouth and promoting his book. This is good news for OWCP.

[I-Glow]

Thanks for posting the information about the ongoing investigation by the SEC.

[I-Glow]

Using fraudulent documents supplied by OWCP - I suggest you read the complaint.

"On or around August 18, 2014, OWC provided an opinion letter to its transfer agent from a disbarred attorney in connection with its issuance of stock to Intiva."

Ouch, the the truth about the OWCP scam hurts.

IG

[surfkast]

Again, the TA must have gotten authorization from a listed executive/the company to be authorized to accept documents from Jeff Friedland who was an investor then a consultant.

Mr. Friedland, through one of his entities, was an early investor in the Registrant, having purchase more than 1.3 million shares of the Registrant’s common stock in 2014 in a private placement. In addition, in February 2016, Mr. Friedland was issued an additional 5.1 million shares through another of his entities (both of which are Friedland Defendants) as compensation for a two-year consulting agreement with the Registrant which agreement expired by its terms in February 2018.

[Italia77]

Where I see if TA is gagged?
I want understand if they are diluting to raise funds....

[Smallville]

Hmmmmm....and this after VERT has been on the ask for awhile.

Has the T/A always been gagged?

[EasternTimeZone]

Jeff Friedland was fraudulent with the TA agent and 2 brokers in 2017, not OWC or OWCP.

This was a cleaning house event. Snake in the grass is revealed and now the stock can climb.

$OWCP closed green today because investors know this.


https://www.prnewswire.com/news-releases/owc-pharmaceutical-research-corp-issues-chairmans-statement-to-shareholders-300610781.html



$OWCP Long and Strong

[MjMilo]

As per usual every point you make in your post is a stretch and doesn't indicate on any level that OWCP has any fault in this action.

So what if Friedland hosted a dinner and used information provided by DR. Baruch.

Dr. Baruch is a pioneer in Israel in the medical mj field for treatment purposes..


Why wouldn't his accomplishments and experience be relied upon?

Your musings and implications are just that and require a stretch...

So any smart investor here will not be rattled by this drivel unless they haven't done proper dd..

You and others that imply OWCP is headed for the garbage heap and a halt or delisting..or the greys must be kidding if you think anyone believes this nonsense.
As I said in a previous post, there are too many exemplary minds/people involved with this company for it to be what you say it is.

Thanks for the laughs!

[Italia77]

I today email the TA
asking if share structure is still
147M O/S and 500 A/S
the answer was:
"Please note it is our policy to only disclose this information to the individuals authorized by the company. You will need to contact OWCP directly for more information."

Mail you too maybe you will have more luck
at [e-mail]

The TA is www.VStockTransfer.com

[nlightn]

moxa,...I think the concerns you and I had about the transfer agent kind of got resolved by Hirsch's correspondence to shareholders. Additionally, many posters on this forum created clarity on the real definitions and content in the SEC Complaint.

OWCP is in the clear.

This is getting very intriguing !

[surfkast]

Who told the TA that Friedland, an advisor, was an authorized representative? It has to be a company executive.

[gruber72]

Yes, don't reply back, but post the truth against the misinformation in a New Post, rather than a reply. The lies can't go unanswered.

[gruber72]

Thank you for posting that clarification. We need the TRUTH to reign here, because there is a lot of misinformation being peddled.

Keep it up, all of you who are fighting the lies.

[Mariner93]

That's not bad news that the SEC press release indicates that the investigation is ongoing.

I've already stated this once and will repeat it - one should use good judgement with what he / she posts about OWCP. It's already been posted on a couple boards that several aliases were shared with the SEC investigators about concerns that multiple posts weren't outside the lines.

Just because a post passes I-Hub's terms of service doesn't mean in this situation that it will be deemed okay by the investigators if multiple misleading posts led to unjust enrichment.

Good luck to all.

[PhenixBleu]

SEC Press Release & Complaint against Friedland, Intiva, and Global Corporate Strategies

SEC Press Release:

https://www.sec.gov/news/press-release/2018-34

SEC Complaint:

https://www.sec.gov/litigation/complaints/2018/comp-pr2018-34.pdf

[moxa1]

Ya me too.

[surfkast]

SEC Complaint
https://www.sec.gov/litigation/complaints/2018/comp-pr2018-34.pdf

Washington D.C., March 8, 2018 —
The Securities and Exchange Commission has filed fraud charges in a scheme to inflate the share price of an Israeli medical marijuana company’s common stock. The court today entered a partial asset freeze of the proceeds of the alleged fraud.

The SEC’s complaint, which was filed on March 5 in federal district court in Denver, alleges that Colorado resident Jeffrey O. Friedland touted OWC Pharmaceutical Research Corp. while misrepresenting both his own investment in OWC and the true nature of his professional relationship with the company. As alleged in the complaint, Friedland was compensated with more than five million OWC shares for handling the company’s media and investor relations efforts. Friedland then touted OWC to media, industry, and investors, creating the false impression that he was merely an early investor in OWC and later, a member of its advisory board, without disclosing his role as a paid promoter. Friedland is alleged to have sold his OWC shares for almost $7 million, after which he and his spouse placed a portion of the proceeds in a investment account in the name of Lane 6552, acquired two homes in all-cash purchases, and made other purchases and uses of the funds. Friedland’s sales took place from March through September 2017 and were made through accounts in the names of Lane 6552 LLC and Intiva Pharma LLC. The United States District Court today, among other things, froze certain accounts that received proceeds of Lane 6552’s sales of OWC stock.

“Corporate insiders and hired experts must not be allowed to profit at the expense of retail investors by concealing the true nature of their interests and investments in companies,” said Associate Director Melissa Hodgman. “If we determine that fraudsters are spending their illicit profits, the staff will act quickly to protect those assets in hopes of returning them to harmed shareholders.”

The SEC’s complaint charges Friedland, Global Corporate Strategies LLC, and Intiva Pharma LLC with violations of Sections 17(a) and (b) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The SEC is seeking injunctions, disgorgement, prejudgment interest, penalties, and penny stock bars. The complaint also named Kathy B. Friedland, Lane 6552 LLC, Aspen Upper Ranch LLC, Assurance Management, LLC, and the Jeffrey and Kathy Friedland Irrevocable Trust as relief defendants.

The investigation has been conducted by Michael T. Grimes, Keith O’Donnell, William Connolly, Shipra G. Wells, and Josh Felker, and supervised by Melissa R. Hodgman. Christian Schultz and Timothy Halloran will lead the SEC’s litigation under the supervision of Fred Block. The SEC appreciates the assistance of Financial Industry Regulatory Authority.

The SEC’s investigation is ongoing.

###

https://www.sec.gov/news/press-release/2018-34

[stockfan100]

Agreed! I was doing well on that too but had to say how funny the link joke was.

[Wormking777]

Shepard Smith Edwards & Kantas. Write this down , you might need this lawyers in a few months to recover your losses after suspension.The least I can do.

[lokelo113]

Im loading up! Thanks for the bargain prices!
IM SOOOO HAPPY HAHAHAHA!!!
Goodbye shorts!

[KrakenTaken]

wishing everyone here nothing but success may the winds be at your backs and may you all make a ton of money here

[stockfan100]

Good one!

[scion]

SEC Obtains Partial Asset Freeze of Proceeds in Alleged Fraudulent Touting Scheme

FOR IMMEDIATE RELEASE
2018-34

SEC Complaint
https://www.sec.gov/litigation/complaints/2018/comp-pr2018-34.pdf

Washington D.C., March 8, 2018 —
The Securities and Exchange Commission has filed fraud charges in a scheme to inflate the share price of an Israeli medical marijuana company’s common stock. The court today entered a partial asset freeze of the proceeds of the alleged fraud.

The SEC’s complaint, which was filed on March 5 in federal district court in Denver, alleges that Colorado resident Jeffrey O. Friedland touted OWC Pharmaceutical Research Corp. while misrepresenting both his own investment in OWC and the true nature of his professional relationship with the company. As alleged in the complaint, Friedland was compensated with more than five million OWC shares for handling the company’s media and investor relations efforts. Friedland then touted OWC to media, industry, and investors, creating the false impression that he was merely an early investor in OWC and later, a member of its advisory board, without disclosing his role as a paid promoter. Friedland is alleged to have sold his OWC shares for almost $7 million, after which he and his spouse placed a portion of the proceeds in a investment account in the name of Lane 6552, acquired two homes in all-cash purchases, and made other purchases and uses of the funds. Friedland’s sales took place from March through September 2017 and were made through accounts in the names of Lane 6552 LLC and Intiva Pharma LLC. The United States District Court today, among other things, froze certain accounts that received proceeds of Lane 6552’s sales of OWC stock.

“Corporate insiders and hired experts must not be allowed to profit at the expense of retail investors by concealing the true nature of their interests and investments in companies,” said Associate Director Melissa Hodgman. “If we determine that fraudsters are spending their illicit profits, the staff will act quickly to protect those assets in hopes of returning them to harmed shareholders.”

The SEC’s complaint charges Friedland, Global Corporate Strategies LLC, and Intiva Pharma LLC with violations of Sections 17(a) and (b) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5. The SEC is seeking injunctions, disgorgement, prejudgment interest, penalties, and penny stock bars. The complaint also named Kathy B. Friedland, Lane 6552 LLC, Aspen Upper Ranch LLC, Assurance Management, LLC, and the Jeffrey and Kathy Friedland Irrevocable Trust as relief defendants.

The investigation has been conducted by Michael T. Grimes, Keith O’Donnell, William Connolly, Shipra G. Wells, and Josh Felker, and supervised by Melissa R. Hodgman. Christian Schultz and Timothy Halloran will lead the SEC’s litigation under the supervision of Fred Block. The SEC appreciates the assistance of Financial Industry Regulatory Authority.

The SEC’s investigation is ongoing.

###

https://www.sec.gov/news/press-release/2018-34

[Hercules1]

Some massive buys here.

Something is going on at OWCP.

[Hercules1]

This stock is significantly undervalued.

Anything under $1.50 is a steal.

[AlexSwiss]

Amazing BUYING PRESSURE AT 0.26$!!!
250k just passed support is unbelievable ready to fly

Reversal this time will be insane

OWCP $$$$

[EasternTimeZone]

blah blah blah.... WRONG! Read the SEC action. OWC did not provide the opinion letter in 2017. It was Friedland that provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552.


43. On or about January 14, 2017, Friedland submitted a request to OWC’s transfer agent to reissue Global’s 5,134,375 shares of OWC stock to Lane 6552 LLC and remove the restricted legend from the securities.
44. Restricted securities are securities acquired in unregistered, private sales from the issuing company or from an affiliate of the issuer. Investors typically receive restricted securities through private placement offerings, Regulation D offerings, employee stock benefit plans, as compensation for professional services, or in exchange for providing “seed money” or start-up capital to the company. When investors acquire restricted securities, they must find an exemption from the SEC’s registration requirements to sell the securities in a public marketplace.
45. In order to sell his restricted shares in the public marketplace, Friedland needed to have OWC’s transfer agent remove the restricted legend on Global’s 5,134,375 shares.
46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney.

[stockfan100]

There were near 20 patent jokes today but we still had near 7 million shares exchanged hands and price didn't go down. The patent jokes are fading by the day.

[gruber72]

The attempts to make OWCP into a scam are even more amusing.

[truffleberry]

Bought more today! Thanks for the cheapies!

[I-Glow]

Complete nonsense - a provisional patent would provide protection if there was any substance to the patent applications.

All pharmaceutical companies publish the efficacy report without the non-provisional patents being approved.

The attempts to defend the OWCP scam are pretty amusing but never accurate.

IG